Sodium Chloride Infusion IV 0.9% 250ml

Name: Sodium Chloride Infusion IV 0.9% 250ml
Brand: Shijiazhuang No. 4 Pharmaceutical Co., Ltd.
SKU: 2264418275

Hebei, ChinaShijiazhuang No. 4 Pharmaceutical Co., Ltd.

US$0.15

20,010 bottle

Sample price:US$0.15/bottle.Request sample

Product profile

Customization

Available

Application

Internal Medicine

Usage Mode

Intravenous (IV) Infusion

Model NO.

Sodium

Suitable for

Elderly, Children, Adult

State

Liquid

Shape

Infusion

Type

Inorganic Chemicals

Pharmaceutical Technology

Chemical Synthesis

Generic Name

Sodium Chloride 0.9% Injection

Active Ingredients

Sodium Chloride (Nacl) 0.9% W/V

Specification

0.9% 250ml

Trademark

SHIMEN

Origin

Hebei, China

HS Code

3004909099

Key features

GMP Certified Manufacturing: Produced under strict GMP standards by Shijiazhuang No.4 Pharmaceutical Co., Ltd.

Global Pharmacopoeia Compliance: Meets BP, EP, and ChP pharmacopoeia standards for international quality.

OEM Customization Available: Customized packaging and labeling services available for OEM orders.

Comprehensive Registration Support: Supporting documents like COPP, CTD, and Free Sale Certificate provided.

Sterile and Pyrogen-Free: Clear, colorless isotonic solution ensuring safety for intravenous use.

Versatile Clinical Application: Used for fluid replenishment, electrolyte balance, and medication dilution.

Flexible Packaging Options: Available in IV bags or bottles made from PVC or non-PVC materials.

Long Shelf Life Stability: Ensures product efficacy with a 36-month shelf life when stored correctly.

Company profile

Shijiazhuang No. 4 Pharmaceutical Co., Ltd.

Hebei, China

Business Type: Manufacturer/FactoryExport Year: 2002-01-01Nearest Port: Tianjin Xingang, Qingdao, ShanghaiAverage Response Time: ≤18hTerms of Payment: LC, T/TInternational Commercial Terms(Incoterms): FOB, CFR, CIF, CIP, EXW

AI-Powered supplier vetting

SummaryShijiazhuang No. 4 Pharmaceutical Co., Ltd. is identified as a Chinese public pharmaceutical manufacturer based in Hebei, with products spanning infusion solutions, injections, tablets, capsules, inhalation products, and other medical materials. The supplier reports ISO 9001, ISO 14001, and GMP certifications, more than ten production lines, automated and information-based production and logistics processes, and substantial stated output across several dosage forms. Its export activity began in 2002, although exports represent only 1%–10% of total sales. The company describes integrated R&D, manufacturing, and marketing capabilities, but the provided information does not establish specific after-sales programs, customization services, or named customer cases. Financial strength cannot be assessed because financial data is excluded.

Supplier typeThe supplier is explicitly classified as a Manufacturer/Factory and is described as an integrated pharmaceutical enterprise covering R&D, industrial production, and marketing. Its listed business covers health and medicine products, including injections, infusion solutions, tablets, capsules, and related dosage forms.

CertificationsThe supplier reports ISO 9001, ISO 14001, and GMP certifications. It also states that production is organized strictly according to GMP requirements, providing explicit evidence of formal quality, environmental, and pharmaceutical manufacturing systems.

R&D capabilityThe supplier describes an integrated R&D, production, and marketing model, reports 50 R&D engineers, and states that its production lines integrate leading equipment and technology at an international advanced level. This supports established technical and development capability, although no specific patents, new-product results, or R&D investment details are provided.

Production capacityProduction capability is strongly supported by more than ten production lines, automated and information-based production and logistics processes, and stated annual outputs of 1.5 billion large-volume injection units and 1 billion units each for tablets, capsules, and small-volume injections. The company also reports more than ten international advanced infusion-solution lines and exports through both agency and self-operated channels.